AI assistant
J.B. Chemicals & Pharmaceuticals Lt — Call Transcript 2022
Nov 5, 2022
63696_rns_2022-11-05_23f125cc-5324-4e43-991f-50885e789268.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [595 x 156] intentionally omitted <==
November 5, 2022
National Stock Exchange of India Limited Exchange Plaza, 5[th] Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051.
Stock Symbol: JBCHEPHARM
Dear Sir,
Subject: Investors/analysts call with management
Ref.: Disclosure under regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has scheduled a conference call for investors and analysts on Monday, November 14, 2022 at 3.30 p.m. IST to discuss its results and developments for the second quarter ended September 30, 2022.
All interested investors/ analysts may join using the following dial-in numbers:
Universal Dial-in Number (India): +91 22 6280 1141/ +91 22 7115 8042
International Numbers
Hong Kong Local Access Number: 800 964 448 Singapore Local Access Number: 800 101 2045 UK Local Access Number: 0 808 101 1573
USA Local Access Number: 1 866 746 2133
==> picture [596 x 179] intentionally omitted <==
==> picture [595 x 156] intentionally omitted <==
The document containing the link for registration and log-in to join the said conference call is attached herewith. Alternatively, the investor/analysts can also log on to the Company’s website www.jbpharma.com to register and join the said conference call.
The schedule of the meeting may change due to exigencies.
We request you to take this on record.
Thanking you,
Yours faithfully,
For J.B. Chemicals & Pharmaceuticals Limited
Digitally signed by Sandeep Anil Phadnis Sandee DN: c=IN, o=Personal, 2.5.4.20=3cf6eb0200f976a58369e39 fde8b8876481484d38598145f6e21f 446bb743f2e, postalCode=411038, st=Maharashtra, p Anil serialNumber=cc500fdd638e71336f c58b204e2ba05ea7c4ade49b8fe43 8e8f254c300dec735, cn=Sandeep Anil Phadnis Phadnis Date: 2022.11.05 14:08:38 +05'30' Sandeep Phadnis Vice President – Secretarial & Company Secretary
==> picture [596 x 179] intentionally omitted <==
==> picture [195 x 173] intentionally omitted <==
==> picture [104 x 115] intentionally omitted <==
JB Pharma Q2 FY23 Earnings Conference Call on Monday, November 14, 2022 at 3:30 PM IST
JB Pharma (J B Chemicals and Pharmaceuticals Ltd.), one of the fastest growing pharmaceutical companies in India, will host a conference call for investors and analysts on Monday, November 14, 2022 at 3:30 PM IST to discuss its results and developments for the second quarter ended 30[th] September, 2022. The financial results will be announced on the 11[th] of November, 2022.
The senior management of JB Pharma will be present to address the call.
| Details of the conference call are as follows: | ||
|---|---|---|
| Timing | 3:30-4:30 pm IST Monday, November 14, 2022 | |
| To enable participants to connect to the conference call without having to wait | ||
| for an operator, please register at the below mentioned link. | ||
| Pre-registration | ||
| You will receive dial in numbers, passcode and a pin for the concall on the | ||
| registered email address provided by you. Kindly dial into the call on the | ||
| Conference Call date and use thepasscode &pin to connect to call. | ||
| Universal Dial-in Number (India) | +91 22 6280 1141 +91 22 7115 8042 |
|
| Hong Kong Local Access Number | 800 964 448 | |
| Singapore Local Access Number | 800 101 2045 | |
| UK Local Access Number | 0 808 101 1573 | |
| USA Local Access Number | 1 866 746 2133 | |
| For further information please contact: | ||
| Lakshay Kataria | Jason D’Souza | Siddharth Rangnekar |
| Chief Financial Officer | Vice President | Shruti Joshi |
| JB Pharma | JB Pharma | CDR India |
| Tel: +91 22 2439 5200 / 2439 5500 | Tel: +91 982 021 5005 | Tel: +91 932 174 0537 / 750 656 7349 |
| Email: [email protected] | Email: [email protected] | Email: [email protected] |
| [email protected] |
==> picture [138 x 71] intentionally omitted <==